Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)
A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Medullary Thyroid Carcinoma(ALTER01031)
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Listed as NCT02586350, this PHASE2/PHASE3 trial focuses on Medullary Thyroid Carcinoma and remains completed. Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., it has been updated 8 times since 2015, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Jun 2019 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
Status: Recruiting → Completed
-
Jan 2019 — Jun 2019 [monthly]
Recruiting PHASE2_PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2019 [monthly]
Recruiting PHASE2_PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Jul 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Changchun, China , Changsha, China , Chongqing, China , Fuzhou, China , Guozhou, China , Hangzhou, China , Harbin, China , Kunming, China , Lanzhou, China and 6 more locations